The National Cancer Institute has announced that they will begin a new study in which cancer patients will be sorted into treatment groups based on genetic mutations in their tumors as opposed to cancer type. This research aims to identify whether targeting molecular abnormalities in cancer is a more effective treatment than traditional labeling of cancer types.
“Precision medicine”, as it has been dubbed, is the result of over a decade of attempting to create more efficient means of treating cancer by matching drugs to the patients who will best benefit from them. James H. Doroshow, director of the division of cancer treatment and diagnosis at the National Cancer Institute states, “[the effort] is the largest and most rigorous precision oncology trial that’s ever been attempted,” and is expected to cost 30 to 40 million dollars to undertake. the NCI hopes to receive additional funding from Congress.
The project plans to initiate screening for participants on July 1st of this year. More>>